



**Pfizer Limited**

The Capital, 1802 / 1901,  
Plot No. C - 70, G Block, Bandra Kurla Complex,  
Bandra (East), Mumbai 400 051.  
Tel : +91 22 6693 2000 Fax : +91 22 2654 0274

July 14, 2020

The Corporate Relationship Dept.  
BSE Limited  
1<sup>st</sup> Floor, P.J.Towers  
Dalal Street, Fort  
Mumbai - 400 001  
Scrip Code: 500680

The Manager, Listing Dept.  
The National Stock Exchange of India Ltd.  
Exchange Plaza, 5<sup>th</sup> Floor,  
Plot No. C/1, G Block  
Bandra-Kurla Complex, Bandra (E)  
Mumbai - 400 051  
Scrip Symbol: PFIZER

Dear Sirs,

**Sub: Disclosure under Regulation 23(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations')**

Pursuant to Regulation 23(9) of the Listing Regulations, please find enclosed, disclosure of related party transactions on a consolidated basis, in the format specified in the accounting standards for the year ended March 31, 2020.

The said disclosure is also available on the website of the Company i.e., [www.pfizerindia.com](http://www.pfizerindia.com)

Please take the above on record.

Thanking you,

Yours truly,

**For Pfizer Limited**

**Prajeet Nair**  
**Company Secretary**

**Encl: A/a**

CIN: L24231MH1950PLC008311

✉ [contactus.india@pfizer.com](mailto:contactus.india@pfizer.com)

🌐 [www.pfizerindia.com](http://www.pfizerindia.com)

# Pfizer Limited

## DISCLOSURE OF RELATED PARTY TRANSACTIONS FOR THE FINANCIAL YEAR ENDED MARCH 31, 2020

Currency: ₹ in crore

### Related party transactions

#### I. Names of related parties and description of relationships

##### A. Parties where control exists:

Ultimate holding company:  
Pfizer Inc., USA

##### B. Companies collectively exercising significant influence:

Pfizer East India B.V., Netherlands  
Wyeth LLC, USA  
Wyeth Holdings Corporation, USA  
John Wyeth & Brother Limited, UK  
Warner - Lambert Company, LLC, USA  
Parke - Davis & Company, LLC, USA  
Pharmacia Corporation, USA  
[Collectively holding 63.92% of the aggregate of equity share capital of the Company]

##### C. Fellow subsidiaries with whom transactions have taken place during the year

Pfizer Products India Private Limited, India  
Pfizer Innovative Supply Point International BVBA, Belgium  
Pfizer Service Company BVBA, Belgium  
Pfizer Worldwide Services, Ireland  
Pfizer Asia Manufacturing PTE, Singapore  
Pfizer Canada Inc

##### D. Key managerial personnel

Mr. S. Sridhar - Managing Director  
Mr. Milind Patil - Wholetime Director & Chief Financial Officer  
Mr. Vivek Dhariwal - Wholetime Director ( upto 14 February 2020)  
Mr. Samir Kazi (w.e.f 14 February 2020)  
Dr. Anurita Majumdar - Wholetime Director ( upto 8 March 2019)  
Mr. R A Shah - Independent Director  
Mr. Pradip Shah - Independent Director  
Mr. Uday Khanna - Independent Director  
Mr. Sunil Lalbhai - Independent Director  
Ms.Meena Ganesh - Independent Director

##### E. Relative of Key managerial personnel

Mr. Akhilesh Iyer ( w.e.f 20 February 2019)

Pfizer Limited

DISCLOSURE OF RELATED PARTY TRANSACTIONS FOR THE FINANCIAL YEAR ENDED MARCH 31, 2020

Currency: ₹ in crore

Related party transactions (Continued)

II. Transactions during the year and balances outstanding as at the year end with the related parties are as follows:

No. Nature of transactions	31 March 2020				31 March 2019			
	Ultimate holding company	Companies exercising significant influence	Fellow subsidiaries	Total	Ultimate holding company	Companies exercising significant influence	Fellow subsidiaries	Total
1 Service income	-	-	55.19	55.19	0.37	-	50.56	50.93
2 Recovery of expenses	0.54	0.03	0.19	0.76	-	-	0.36	0.36
3 Purchase of stock-in-trade	-	-	393.41	393.41	-	-	396.42	396.42
4 Purchase of raw / bulk materials	-	-	115.05	115.05	-	-	49.98	49.98
5 Reimbursement of expenses	-	-	-	-	0.27	-	-	0.27
6 Dividend in respect of the year ended 31 March 2020/ 2019	-	65.77	-	65.77	-	58.49	-	58.49
7 Liability written back	-	1.42	8.59	10.01	-	-	-	-
No. Nature of transactions	31 March 2020				31 March 2019			
	Ultimate holding company	Companies exercising significant influence	Fellow subsidiaries	Total	Ultimate holding company	Companies exercising significant influence	Fellow subsidiaries	Total
8 Outstanding as at the year end – Due from	0.54	0.09	20.99	21.62	0.33	0.06	19.21	19.60
9 Outstanding as at the year end – Due to	11.18	6.47	271.20	288.85	10.52	7.84	254.97	273.33

Key managerial personnel

No. Nature of transactions	Year ended 31 March 2020	Year ended 31 March 2019
1 Remuneration to key management personnel *	9.22	10.50

\* Excludes amounts payable to key management personnel towards gratuity and compensated absences.

Details of material transactions during the year:

	Year ended 31 March 2020	Year ended 31 March 2019
<b>a) Service income</b>		
Pfizer Products India Private Limited	25.60	23.22
Pfizer Worldwide Services	29.59	27.34
<b>b) Recovery of expenses</b>		
Pfizer Products India Private Limited	0.19	0.34
Pfizer Inc., USA	0.54	-
<b>c) Purchase of stock in trade</b>		
Pfizer Innovative Supply Point Intl BVBA, Belgium	80.21	258.18
Pfizer Service Company BVBA, Belgium	300.36	131.93
<b>d) Purchase of raw/ bulk materials</b>		
Pfizer Service Company BVBA, Belgium	111.62	46.87
<b>e) Reimbursement of expenses</b>		
Pfizer Inc., USA	-	0.27
<b>f) Dividend paid</b>		
Pfizer East India B.V.	40.92	36.37
Wyeth LLC, USA	12.64	11.24
<b>g) Remuneration to key management personnel</b>		
S. Sridhar	4.11	3.55
Milind Patil	2.10	1.59
Vivek Dhariwal	1.88	2.53
Samir Kazi	0.16	-
Dr. Anurita Majumdar	-	1.96

Pfizer Limited

DISCLOSURE OF RELATED PARTY TRANSACTIONS FOR THE FINANCIAL YEAR ENDED MARCH 31, 2020

Currency: ₹ in crore

Related party transactions (Continued)

	As on 31 March 2020	As on 31 March 2019
<b>h) Outstanding as at the year end due from</b>		
Pfizer Worldwide Services	5.70	5.47
Pfizer Products India Private Limited, India	15.29	13.74
<b>i) Outstanding as at the year end due to</b>		
Pfizer Innovative Supply Point Intl BVBA, Belgium	15.81	62.49
Pfizer Service Company BVBA, Belgium	152.55	83.97
Pfizer Export Company, Ireland	82.85	84.70